![Michael Grissinger](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Grissinger
Directeur/Bestuurslid bij AKARI THERAPEUTICS, PLC
Vermogen: 8 996 $ op 31-05-2024
Profiel
Michael Grissinger is currently the Chairman at Kira Biotech Pty Ltd., Director at Atrin Pharmaceuticals LLC, Independent Director at Akari Therapeutics Plc, Independent Director at Aprea Therapeutics, Inc., Director at Atriva Therapeutics GmbH, and Director at Envisagenics, Inc. Previously, he served as an Independent Director at resTORbio, Inc., Director at Atrin Pharmaceuticals, Inc., Member-Management Board at Janssen Pharmaceuticals, Inc., and VP & Head-Pharmaceutical Corporate Development at Johnson & Johnson.
He holds an undergraduate degree from Juniata College and an MBA from Fox School of Business.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
APREA THERAPEUTICS, INC.
0.03% | 20-06-2024 | 1 844 ( 0.03% ) | 8 796 $ | 31-05-2024 |
AKARI THERAPEUTICS PLC
0.09% | 24-05-2024 | 20 000 000 ( 0.09% ) | 200 $ | 31-05-2024 |
Actieve functies van Michael Grissinger
Bedrijven | Functie | Begin |
---|---|---|
AKARI THERAPEUTICS, PLC | Directeur/Bestuurslid | 23-01-2018 |
APREA THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-05-2022 |
Atrin Pharmaceuticals LLC
![]() Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Directeur/Bestuurslid | 01-11-2018 |
Kira Biotech Pty Ltd.
![]() Kira Biotech Pty Ltd. BiotechnologyHealth Technology Kira Biotech Pty Ltd. operates as biotechnology company which develops novel immunomodulatory compounds for the treatment of immune system disorders. The company was founded by Georgina Clark is headquartered in Brisbane, Australia. | Voorzitter | 30-07-2020 |
Atriva Therapeutics GmbH
![]() Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Directeur/Bestuurslid | 01-12-2020 |
Envisagenics, Inc.
![]() Envisagenics, Inc. BiotechnologyHealth Technology Envisagenics, Inc. engages in developing of artificial intelligence platform for discovering drugs. The company was founded by Maria Luisa Pineda and Martin Akerman and is headquartered in New York, NY. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Michael Grissinger
Bedrijven | Functie | Einde |
---|---|---|
ADICET BIO, INC. | Directeur/Bestuurslid | 15-09-2020 |
JOHNSON & JOHNSON | Corporate Officer/Principal | 01-01-2018 |
Atrin Pharmaceuticals, Inc.
![]() Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Directeur/Bestuurslid | - |
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Opleiding van Michael Grissinger
Juniata College | Undergraduate Degree |
Fox School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
AKARI THERAPEUTICS, PLC | Health Technology |
APREA THERAPEUTICS, INC. | Health Technology |
JOHNSON & JOHNSON | Health Technology |
Bedrijven in privébezit | 7 |
---|---|
Janssen Pharmaceuticals, Inc.
![]() Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
resTORbio, Inc.
![]() resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
Atrin Pharmaceuticals LLC
![]() Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Health Technology |
Kira Biotech Pty Ltd.
![]() Kira Biotech Pty Ltd. BiotechnologyHealth Technology Kira Biotech Pty Ltd. operates as biotechnology company which develops novel immunomodulatory compounds for the treatment of immune system disorders. The company was founded by Georgina Clark is headquartered in Brisbane, Australia. | Health Technology |
Atrin Pharmaceuticals, Inc.
![]() Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Health Technology |
Atriva Therapeutics GmbH
![]() Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Health Technology |
Envisagenics, Inc.
![]() Envisagenics, Inc. BiotechnologyHealth Technology Envisagenics, Inc. engages in developing of artificial intelligence platform for discovering drugs. The company was founded by Maria Luisa Pineda and Martin Akerman and is headquartered in New York, NY. | Health Technology |